MedPath

Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis

Phase 1
Completed
Conditions
Arthritis, Rheumatoid
Glioma
Brain Cancer
Central Nervous System Neoplasms
Interventions
Radiation: [18F]FHBG
Registration Number
NCT00185848
Lead Sponsor
Sanjiv Sam Gambhir
Brief Summary

The purpose of this study is to determine whether \[18F\]FHBG is suitable for use as an imaging probe in cancer or rheumatoid arthritis patients enrolled in cell or gene therapy trials. In this phase 1 study we will assess the safety and biodistribution of \[18F\]FHBG in patients.

Detailed Description

The success of cell and gene therapy depends on specific targeting of the therapeutic gene or cell that is administered to the patient. Our goal is to develop an imaging method to non-invasively monitor the location of the therapeutic gene or cell. Imaging should help in the design of better protocols and potentially reduce side-effects of cell and gene therapy.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria
  • Clinical diagnosis of brain tumor or rheumatoid arthritis
Exclusion Criteria
  • Below 18 years of age

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
[18F]FHBG arm[18F]FHBG-
Primary Outcome Measures
NameTimeMethod
The primary endpoint of the study for each patient is acquisition of PET/CT image.Time of scan
Secondary Outcome Measures
NameTimeMethod
Collection of vital signs, EKG, blood chemistry and CBC dataday 1, 2 and 8.

Trial Locations

Locations (2)

University of California Los Angeles

🇺🇸

Los Angeles, California, United States

Stanford University School of Medicine

🇺🇸

Stanford, California, United States

© Copyright 2025. All Rights Reserved by MedPath